Guest guest Posted September 23, 2008 Report Posted September 23, 2008 >Admin Admin <admin >UNCENSORED POST: More than half of US >drug safety studies never see the light of day >editor <editor >Wed, 24 Sep 2008 06:56:39 +1200 > > >UNCENSORED POST > >More than half of US drug safety studies >never see the light of day > > ><http://www.guardian.co.uk/science/2008/sep/23/clinical.trials>http://www.guard\ ian.co.uk/science/2008/sep/23/clinical.trials > >Only 43% of the evidence of safety and efficacy >that the US Food and Drug Administration uses to >approve drugs is published in scientific >journals. The authors of the survey say this amounts to " scientific misconduct " > > * James Randerson > * guardian.co.uk, > * Tuesday September 23 2008 10:46 BST > >At a pharmacy. Photograph: Alex Wong/Getty Images > >Photograph: Alex Wong/Getty Images > >The results of more than half of all clinical >trials that demonstrate the safety and >effectiveness of new drugs are not published >within five years of the drug going on the >market, according to an analysis of 90 drugs >approved by US regulators between 1998 and 2000. > >The researchers, who traced the publication or >otherwise of 909 separate clinical trials in the >scientific literature, wrote that the failure of >drug companies to publish the evidence relating >to new medicines amounted to " scientific >misconduct " . They said it " harms the public >good " by preventing informed decisions by >doctors and patients about new medicines and by >hampering future scientific work. > >Sir Iain Chalmers, who is director of the James >Lind Library in Oxford and a founder of the >Cochrane Collaboration, a respected organisation >that reviews medical evidence, said that it was >vital that all data on new medicines be made public. > > " Patients may otherwise suffer or die >unnecessarily, " said Chalmers, who was not >involved in the work. " The people who >participate in a trial have a right to expect >that their participation and their data will be >made available publicly so that people can take >whatever decisions seem appropriate in the light of that information. " > >The US researchers who carried out the study >searched the academic literature for publication >of the trials that drug companies relied on to >convince the US Food and Drug Administration >that their new products were safe and effective >and so worthy of market approval. > >Information that is used to convince the >regulators is not necessarily subsequently >published for public and scientific scrutiny, >but the scale of the missing information was found to be vast. > >Five years after each of the 90 drugs was first >available for patients, only 43% of the studies >supporting the drugs' use had been published, >with most publication happening in the first one >or two years. In the case of one product – an >antibiotic – the researchers could not find a >single supporting trial in the scientific >literature, while five trials were published >twice and one was published three times. > >The team also found evidence for a " publication >bias " . Trials with statistically significant >results were more likely to be published than >those with non-significant results, as were those with larger sample sizes. > > " In the years immediately following FDA approval >that are most relevant to public health, there >exists incomplete and selective publication of >trials supporting approved new drugs, " Prof Ida >Sim and her colleagues at the University of >California, San Francisco, wrote in the journal PLoS Medicine. > >One possible explanation for the scientific data >not being published is that drug companies hold >back publication of the results that are least >flattering to their new drugs. Another >possibility is that academic journal editors are >less inclined to publish papers on trials that >have negative or ambiguous results. > > " Regardless of the cause, publication bias harms >the public good by impairing the ability of >clinicians and patients to make informed >clinical decisions, and the ability of >scientists to design safer and more efficient >trials based on past findings, " the authors >wrote. " Publication bias can thus be considered >a form of scientific misconduct. " > >The reporting of clinical trial results should >have improved since the period analysed by the >researchers, because the 2007 FDA Amendments Act >mandated basic results reporting for all trials >supporting FDA-approved drugs and devices. >However, the researchers said it remained to be >seen whether clinical reporting would improve. > >The new law could even have the opposite effect. > " Might sponsors feel less compelled to publish >equivocal trials because the basic results will >already be in the public domain? " they speculated. >_____________________________\ ___Consider >aspasrtame: FDA originally asked for indictment >of manufacturer, revoked the petition for >approval until Don Rumsfeld called in his >markers and got it marketed, and admitted to >Congress it is a carcinogen and violated the >Delaney Amendment. Yet over a quarter of a >century later it remains on the market with FDA >approval as people die from Rumsfeld Plague all over the world. Dr. Betty Martini, D.Hum, Founder Mission Possible International 9270 River Club Parkway Duluth, Georgia 30097 770 242-2599 www.mpwhi.com, www.dorway.com, www.wnho.net Aspartame Toxicity Center, www.holisticmed.com/aspartame Aspartame Information List, www.mpwhi.com Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.